• 1
    Bladomero H, Gratwohl M, Gratwohl A et al. The EBMT activity survey 2009: Trends over the past 5 years. Bone Marrow Transplant 2011; 46: 485501.
  • 2
    Horowitz MM, Gale RP, Sondel PM et al. Graft versus leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555562.
  • 3
    Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006; 354: 18131826.
  • 4
    Gooley TA, Chien JW, Pergam SA et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010; 363: 20912101.
  • 5
    Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5: 275284.
  • 6
    Gerber JM, Smith BD, Ngwang B et al. A clinically relevant population of leukemia CD34+CD38− cells in acute myeloid leukemia. Blood 2012; 119: 35713577.
  • 7
    Levi I, Grotto I, Yerushalmi R et al. Meta-analysis of autologous bone marrow transplantation versus chemotherapy in adult patients with acute myeloid leukemia in first remission. Leukemia Res 2004; 28: 605612.
  • 8
    Ding L, Ley TJ, Larson DE et al. Clonal evaluation in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012; 481: 506510.
  • 9
    Osawa M, Hanada K, Hamada H et al. Long term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell. Science 1996; 273: 242245.
  • 10
    Lorenze E, Uphoff D, Reid TR et al. Modification of irradiation injury in mice and guinea pigs by bone marrow injections. J Natl Cancer Inst 1951; 12: 197201.
  • 11
    Storb R, Epstein RB, Graham TC et al. Methotrexate regimens for control of graft-versus-host disease in dogs with allogeneic marrow transplantation. Blood Transplantation 1970; 9: 240246.
  • 12
    Thomas ED, Buckner CD, Banaji M et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 1977; 49: 511533.
  • 13
    Thomas ED, Buckner CD, Clift RA et al. Marrow transplantation for acute nonlymphoblastic leukemia in first remission. N Engl J Med 1979; 301: 597599.
  • 14
    Bonnet D, Warren EH, Greenberg PD et al. CD8+ minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc Natl Acad Sci USA 1999; 96: 86398644.
  • 15
    Sorror ML, Giralt S, Sandmaier BM et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: Combined FHCRC and MDACC experiences. Blood 2007; 110: 46064613.
  • 16
    Farina L, Bruno B, Patriarca F et al. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation. Leukemia 2009; 23: 11311138.
  • 17
    Lim ZY, Ingram W, Brand R et al. Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML. Bone Marrow Transplant 2010; 45: 633639.
  • 18
    Hamadani M, Awan FT, Copelan EA. Hematopoietic stem cell transplantation in adults with acute myeloid leukemia. Biol Blood Marrow Transplant 2008; 14: 556567.
  • 19
    Koreth J, Schlenk R, Kopecky KJ et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: Systematic review and metaanalysis of prospective clinical trials. JAMA 2009; 301: 23492361.
  • 20
    Marcucci G, Mrozek K, Ruppert AS et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients from inv(16): A Cancer and Leukemia Group B study. J Clin Oncol 2005; 23: 57055717.
  • 21
    Paschka P, Marcucci G, Ruppert AS et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): A Cancer and Leukemia Group B Study. J Clin Oncol 2006; 24: 39043911.
  • 22
    Cornelissen JJ, van Putten WL, Verdonck LF et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle aged adults: Benefits for whom? Blood 2007; 109: 36583666.
  • 23
    Yanada M, Matsuo K, Emi N et al. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: A metaanalysis. Cancer 2005; 103: 16521658.
  • 24
    Medeiros BC, Othus M, Fang M et al. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: The Southwest Oncology Group (SWOG) experience. Blood 2010; 116: 22242228.
  • 25
    Fang M, Storer B, Estey E et al. Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation. Blood 2011; 118: 14901494.
  • 26
    Kottardis PD, Gale RE, Frew ME et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98: 17521759.
  • 27
    Meshinchi S, Appelbaum FR. Structural and functional alterations of FLT3 in acute myeloid leukemia. Clin Cancer Res 2009; 15: 42634269.
  • 28
    Thiede C, Koch S, Creutzig E et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006; 107: 40114020.
  • 29
    Schlenk RF, Dohner K, Krauter J et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 19091918.
  • 30
    Paschka P, Schlenk RF, Gaidzik VI et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010; 28: 36363643.
  • 31
    Ley TJ, Ding L, Walter MJ et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010; 363: 24242433.
  • 32
    Patel J, Gonen M, Figueroa M et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012; 366: 10791089.
  • 33
    Damm F, Heuser M, Morgan M et al. Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. Blood 2011; 117: 45614568.
  • 34
    Schoch C, Kern W, Schnittger S et al. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): An analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia 2004; 18: 120125.
  • 35
    Chang C, Storer BE, Scott BL et al. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: Similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood 2007; 110: 13791387.
  • 36
    Armand P, Kim HT, DeAngelo DJ et al. Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant 2007; 13: 655664.
  • 37
    Duval M, Klein JP, He W et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol 2010; 28: 37303738.
  • 38
    Clift RA, Buckner CD, Appelbaum FR et al. Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. J Clin Oncol 1992; 10: 17231729.
  • 39
    Breems D, Van Putten W, Hujgens P et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 2005; 23: 19691978.
  • 40
    Powles R. 50 years of allogeneic bone-marrow transplantation. Lancet Oncol 2010; 11: 305306.
  • 41
    Anasetti C, Logan BR, Lee SJ et al. Increased incidence of chronic graft versus host disease (GVHD) and no survival advantage with Filgastrim-mobilized peripheral blood stem cells (PBSC) compared to bone marrow (BM) transplants from unrelated donors: Results of Blood and Marrow Transplant Clincal Trails Network (BMT CTN) Protocol 0201, a Phase III, Prospective Randomized Trial. Blood 2011; 118:abstract 1.
  • 42
    Mielcarek M, Storer B, Martin PJ et al. Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow. Blood 2010; 119: 26752678.
  • 43
    Gupta V, Tallman MS, He W et al. Comparable survival after HLA-well matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. Blood 2010; 116: 18391848.
  • 44
    Saber W, Opie S, Rizzo JD et al. Outcomes after matched unrelated donor vs. identical sibling hematopoietic cell transplantation (HCT) in adults with acute myelogenous leukemia (AML). Blood 2012; 119: 39083916.
  • 45
    Lee S, Klein J, Haagenson M et al. High-resolution donor-recipient HLA matching contribues to the success of unrelated donor marrow transplantation. Blood 2007; 110: 45764583.
  • 46
    Laughlin M, Eapen M, Rubinstein P et al. Outcomes of transplantation of cord blood or bone marrow from unrelated doors in adults with leukemia. N Engl J Med 2004; 351: 22652275.
  • 47
    Eapen M, Rocha V, Sanz G et al. Effect of graft source of unrelated donor hematopoietic stem-cell transplantation in adults with acute leukemia: A retrospective analysis. Lancet 2010; 11: 653660.
  • 48
    Brunstein CG, Gutman JA, Weisdorf DJ et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: Relative risks and benefits of double umbilical cord blood. Blood 2010; 116: 469399.
  • 49
    Ruggeri L, Capanni M, Urbani E et al. Effectiveness of donor natural killer alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 20972100.
  • 50
    Luznik L, O'Donnell PV, Symons HJ et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641650.
  • 51
    Socie G, Clift RA, Blaise D et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: Long-term follow-up of 4 randomized studies. Blood 2001; 98: 35693574.
  • 52
    Sandmaier BM, Storb R. Nonmyeloablative therapy and hematopoietic cell transplantation for hematologic disorders. In: Blume KG, Forman SJ, Appelbaum FR, eds. Thomas' Hematopoietic Cell Transplantation. 3rd ed. Malden, MA: Blackwell Publishing, 2004: 11641176.
  • 53
    Luger SM, Ringden O, Zhang MJ et al. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant 2012; 47: 203211.
  • 54
    Appelbaum F. Preparative regimens and ageism. Biol Blood Marrow Transplant 2011; 17: 14191420.
  • 55
    Alatrash G, de Lima M, Hamerschlak N et al. Myeloablative, reduced toxicity IV busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients in the sixth through eighth decades of life. Biol Blood Marrow Transplant 2011; 17: 14901496.
  • 56
    Farag SS, Archer KJ, Mrozek K et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: Results from Cancer and Leukemia Group B 8461. Blood 2006; 108: 6373.
  • 57
    Champlin R. Reduced-intensity allogeneic hematopoietic transplantation should be considered a standard of care for older patients with acute myeloid leukemia. Biol Blood Marrow Transplant 2011; 17: 17211724.
  • 58
    Vago L, Perna SK, Zanussi M et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med 2009; 361: 478488.